FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.
What happened
FDA inspected the Incheon facility from March 20 to March 24, 2023 and found violations of CGMP (current good manufacturing practice) in incoming component testing, quality oversight, and equipment qualification/calibration. FDA also found that Hand Sanitizer Perfect Care Gel was an unapproved new drug because of a 'sterilizing effect' claim, and that both hand sanitizer labels were misbranded (labeling violations) for lacking required adverse-event contact information. FDA said the company's April 11, 2023 response to the Form FDA 483 (inspection observations) was inadequate.
What FDA found
The firm did not test incoming components, including ethanol, for identity and relied on supplier certificates of analysis without qualifying suppliers.
21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)The quality unit lacked procedures and authority for critical duties such as deviations, CAPA, complaints, recalls, supplier qualification, training, and annual product reviews, and batch records did not identify filling lines.
21 CFR 211.22Equipment used to make drugs, including a water system and a gas chromatograph, was not shown to be qualified, maintained, or calibrated.
21 CFR 211.63Hand Sanitizer Perfect Care Gel is an unapproved new drug because its 'sterilizing effect' claim goes beyond the OTC tentative final monograph and no approved application is in effect.
FD&C Act sections 505(a) and 301(d) (21 U.S.C. 355(a), 331(d))Both hand sanitizer labels lack a domestic address or phone for serious adverse event reports, and Hand Sanitizer Perfect Care Gel does not meet section 505G marketing requirements and has no approved application.
FD&C Act sections 502(x) and 502(ee) (21 U.S.C. 352(x), 352(ee))FDA found no active drug listings for the establishment and said any drug in U.S. commercial distribution must be listed with FDA.
FD&C Act section 510(j)(1) (21 U.S.C. 360(j)(1)); 21 CFR 207.41
What FDA wants
FDA asks the company to respond in writing within 15 working days with what it has done to correct violations and prevent recurrence, or with reasons for delay and a completion schedule. If it plans to make drugs for the U.S. market again, it must notify FDA before resuming and should engage a qualified CGMP consultant.
Who should pay attention
- companies that import or distribute Handock hand sanitizers
- brands using South Korean OTC drug contract manufacturers
- quality teams managing supplier qualification and drug listing
This is a summary. Read the original letter on fda.gov.